Licensing
CyTuVax is open to collaborations with scientific groups and vaccine companies to further explore the wide applicability of its cytokine-depot attached adjuvant and vaccination technology in (pre-) clinical projects.
For further information on licensing opportunities, please contact CEO Dr. Rene Vleugels.